by Sameer Laul | Jan 9, 2023 | News
EpiVax, Inc. is excited to announce that its subsidiary, EpiVax Therapeutics, has signed an exclusive collaboration agreement with GreenLight Biosciences to advance the development of personalized cancer vaccines. The effort will combine GreenLight’s mRNA...
by Riley Nolan | May 13, 2021 | Featured, News
PROVIDENCE, RI, May 13, 2021 /PRNewswire/ — EpiVax Therapeutics, Inc. (“EVT”) announces the publication “Multi‑step screening of neoantigens’ HLA and TCR‑interfaces improves prediction of survival” in Scientific Reports. This study demonstrates a superior method...
by Riley Nolan | Feb 17, 2021 | Events, Featured, Webinars
EpiVax CEO/CSO Annie De Groot hosted a talk for the FDA Office of Tissues and Advanced Therapies (OTAT) group on February 11, 2021. Annie presented the latest on EpiVax’s iVAX Toolkit in her talk “Epitope Selection for Cancer Vaccines”. JanusMatrix,...
by Annie De Groot | Mar 27, 2020 | News
March 26, 2020 04:42 PM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced it has reduced the timeline from biopsy to vaccine to under 4 weeks for its personalized neoantigen...
by Annie De Groot | Nov 12, 2019
Highly efficient selection of tumor neoantigens improves therapeutic cancer vaccine efficacy
by Annie De Groot | Jun 28, 2019 | Events
5th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference CICON 2019: Translating Science into Survival Wednesday, September 25 – Saturday, September 28 Espace Grande Arche de la Defense Parvis de la Défense 92044 Paris, France Members of EpiVax...
by Annie De Groot | Apr 8, 2019
EpiVax_Oncology_TRI-CON_CT26_04Mar19_32w44h